Credit Suisse Ag Inhibrx, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Inhibrx, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 18,561 shares of INBX stock, worth $297,532. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,561

Previous 19,742 5.98%

Holding current value

$297,532

Previous $750,000 13.6%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$32.76 - $39.56 $38,689 - $46,720	-1,181 Reduced 5.98%	18,561 $648,000
Q4 2023 Feb 08, 2024	SELL	$14.5 - $38.0 $45,921 - $120,346	-3,167 Reduced 13.82%	19,742 $750,000
Q3 2023 Nov 13, 2023	SELL	$15.75 - $26.31 $102,280 - $170,857	-6,494 Reduced 22.09%	22,909 $420,000
Q2 2023 Aug 11, 2023	BUY	$16.96 - $27.82 $152,860 - $250,741	9,013 Added 44.2%	29,403 $763,000
Q1 2023 May 10, 2023	BUY	$18.45 - $27.14 $23,505 - $34,576	1,274 Added 6.66%	20,390 $384,000
Q4 2022 Feb 13, 2023	SELL	$20.18 - $33.33 $16,345 - $26,997	-810 Reduced 4.07%	19,116 $471,000
Q3 2022 Nov 10, 2022	BUY	$11.58 - $24.73 $92,246 - $196,999	7,966 Added 66.61%	19,926 $358,000
Q2 2022 Aug 12, 2022	BUY	$8.52 - $25.26 $101,899 - $302,109	11,960 New	11,960 $136,000
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $143,605 - $311,759	-7,220 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $193,135 - $332,264	7,220 New	7,220 $315,000

Others Institutions Holding INBX

# of Institutions

Shares Held

25.3K

Call Options Held

Put Options Held

Advisor Group Holdings, Inc. Phoenix, AZ

6.69K
Shares

$107,240
0.0% of portfolio

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account